Supernus Pharmaceuticals (SUPN) Accounts Payables (2016 - 2026)
Supernus Pharmaceuticals has reported Accounts Payables over the past 15 years, most recently at $107.8 million for Q4 2025.
- Quarterly Accounts Payables rose 41.19% to $107.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.8 million through Dec 2025, up 41.19% year-over-year, with the annual reading at $107.8 million for FY2025, 41.19% up from the prior year.
- Accounts Payables was $107.8 million for Q4 2025 at Supernus Pharmaceuticals, down from $108.6 million in the prior quarter.
- Over five years, Accounts Payables peaked at $133.0 million in Q2 2022 and troughed at $70.1 million in Q1 2021.
- The 5-year median for Accounts Payables is $82.8 million (2023), against an average of $89.9 million.
- Year-over-year, Accounts Payables soared 545.81% in 2021 and then tumbled 37.56% in 2023.
- A 5-year view of Accounts Payables shows it stood at $117.7 million in 2021, then fell by 18.13% to $96.3 million in 2022, then fell by 17.41% to $79.6 million in 2023, then fell by 4.04% to $76.4 million in 2024, then soared by 41.19% to $107.8 million in 2025.
- Per Business Quant, the three most recent readings for SUPN's Accounts Payables are $107.8 million (Q4 2025), $108.6 million (Q3 2025), and $77.7 million (Q2 2025).